134 related articles for article (PubMed ID: 15780569)
1. Prediction by quantitative histology of pathological stage in prostate cancer.
Pepe P; Galia A; Fraggetta F; Grasso G; Allegro R; Aragona F
Eur J Surg Oncol; 2005 Apr; 31(3):309-13. PubMed ID: 15780569
[TBL] [Abstract][Full Text] [Related]
2. Is quantitative histologic examination useful to predict nonorgan-confined prostate cancer when saturation biopsy is performed?
Pepe P; Fraggetta F; Galia A; Grasso G; Piccolo S; Aragona F
Urology; 2008 Dec; 72(6):1198-202. PubMed ID: 19041023
[TBL] [Abstract][Full Text] [Related]
3. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
[TBL] [Abstract][Full Text] [Related]
4. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins.
Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
Urology; 2004 Sep; 64(3):516-21. PubMed ID: 15351582
[TBL] [Abstract][Full Text] [Related]
5. Prediction of pathological stages before prostatectomy in prostate cancer patients: analysis of 12 systematic prostate needle biopsy specimens.
Park EA; Lee HJ; Kim KG; Kim SH; Lee SE; Choe GY
Int J Urol; 2007 Aug; 14(8):704-8. PubMed ID: 17681059
[TBL] [Abstract][Full Text] [Related]
6. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
[TBL] [Abstract][Full Text] [Related]
7. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.
Zlotta AR; Remzi M; Snow PB; Schulman CC; Marberger M; Djavan B
J Urol; 2003 May; 169(5):1724-8. PubMed ID: 12686818
[TBL] [Abstract][Full Text] [Related]
8. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
[TBL] [Abstract][Full Text] [Related]
9. The total percentage of biopsy cores with cancer improves the prediction of pathological stage after radical prostatectomy.
Winkler MH; Khan FA; Kulinskaya E; Hoh IM; McDonald D; Boustead G; Kaisary AV
BJU Int; 2004 Oct; 94(6):812-5. PubMed ID: 15476514
[TBL] [Abstract][Full Text] [Related]
10. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
[TBL] [Abstract][Full Text] [Related]
11. Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Nishimoto K; Nakashima J; Hashiguchi A; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Oya M; Murai M
Int J Urol; 2008 Jun; 15(6):520-3. PubMed ID: 18422574
[TBL] [Abstract][Full Text] [Related]
12. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
[TBL] [Abstract][Full Text] [Related]
13. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
14. Does site specific labeling of sextant biopsy cores predict the site of extracapsular extension in radical prostatectomy surgical specimen.
Taneja SS; Penson DF; Epelbaum A; Handler T; Lepor H
J Urol; 1999 Oct; 162(4):1352-7; discussion 1357-8. PubMed ID: 10492195
[TBL] [Abstract][Full Text] [Related]
15. Prognostic parameters other than Gleason score for the daily evaluation of prostate cancer in needle biopsy.
Algaba F; Arce Y; Oliver A; Barandica C; Santaularia JM; Montañés R
Eur Urol; 2005 Oct; 48(4):566-71. PubMed ID: 16084008
[TBL] [Abstract][Full Text] [Related]
16. Unilateral prostate cancer cannot be accurately predicted in low-risk patients.
Isbarn H; Karakiewicz PI; Vogel S; Jeldres C; Lughezzani G; Briganti A; Montorsi F; Perrotte P; Ahyai SA; Budäus L; Eichelberg C; Heuer R; Köllermann J; Sauter G; Schlomm T; Steuber T; Haese A; Zacharias M; Fisch M; Heinzer H; Huland H; Chun FK; Graefen M
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):784-7. PubMed ID: 19864083
[TBL] [Abstract][Full Text] [Related]
17. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
[TBL] [Abstract][Full Text] [Related]
18. Does prostate biopsy Gleason score accurately express the biologic features of prostate cancer?
Stav K; Judith S; Merald H; Leibovici D; Lindner A; Zisman A
Urol Oncol; 2007; 25(5):383-6. PubMed ID: 17826654
[TBL] [Abstract][Full Text] [Related]
19. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
20. The independent impact of extended pattern biopsy on prostate cancer stage migration.
Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
